And in North Texasespecially in LewisvilleI see a lot of folks who just want to keep up with life, not necessarily reverse time
That means we have limited data on how these drugs work in the real world for diverse patients, and we risk reinforcing disparities if access remains limited
Starting July 1, 2026, Medicare will cover FDA-approved weight-loss medications like Wegovy (semaglutide) and Zepbound (tirzepatide) for a flat $50 per month through a new initiative called the Medicare GLP-1 Bridge Program
When someone first starts treatment with a GLP-1 receptor agonist, we slowly introduce the medication for a reason theres a risk of gastrointestinal side effects as your body gets used to the drug
Additional studies, particularly of GLP-1 RA, GIP and GLP-1 RA, and SGLT2i, will hopefully provide new avenues to reduce mortality in this population, in which there are enormous health disparities